Derek Leaderer

Derek Leaderer, MD, PhD

University Of Florida School Of Medicine

Department: MD-SURGERY-VASCULAR
Business Phone: (352) 265-0916

About Derek Leaderer

Hometown: Guilford, CT

Clinical Interests: Vascular Surgery

What were you looking for in a residency program? ‚Äč

A place where I would get exceptional training and look forward to coming to work every day

What are the strengths of the UF program?

Large case volume with sick and complex patients

Great co-residents who look out for one another

Faculty that are engaged in the education process

What do you like best about living in Gainesville?

Ease of living, close commute

List of hobbies/interests:

Spending time with my family (wife, two young kids and dog)

Publications

2020
Neonatal Dieulafoy Lesion Requiring Massive Transfusion Protocol and Surgical Intervention.
Neonatology. 117(3):380-383 [DOI] 10.1159/000506704. [PMID] 32325456.
2016
G-quartet oligonucleotide mediated delivery of proteins into photoreceptors and retinal pigment epithelium via intravitreal injection.
Experimental eye research. 145:380-392 [DOI] 10.1016/j.exer.2016.02.009. [PMID] 26923800.
2015
Adeno-associated virus mediated delivery of an engineered protein that combines the complement inhibitory properties of CD46, CD55 and CD59.
The journal of gene medicine. 17(6-7):101-15 [DOI] 10.1002/jgm.2829. [PMID] 25917932.
2015
Topical application of a G-Quartet aptamer targeting nucleolin attenuates choroidal neovascularization in a model of age-related macular degeneration.
Experimental eye research. 140:171-178 [DOI] 10.1016/j.exer.2015.09.005. [PMID] 26368850.
2013
Potential cancer-related role of circadian gene TIMELESS suggested by expression profiling and in vitro analyses.
BMC cancer. 13 [DOI] 10.1186/1471-2407-13-498. [PMID] 24161199.
2012
An environmental epigenetic study of ADRB2 5′-UTR methylation and childhood asthma severity.
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology. 42(11):1575-81 [DOI] 10.1111/j.1365-2222.2012.04055.x. [PMID] 22862293.
2012
Genetic and epigenetic associations of circadian gene TIMELESS and breast cancer risk.
Molecular carcinogenesis. 51(12):923-9 [DOI] 10.1002/mc.20862. [PMID] 22006848.
2011
Ambrisentan for pulmonary arterial hypertension due to congenital heart disease.
The American journal of cardiology. 107(9):1381-5 [DOI] 10.1016/j.amjcard.2010.12.051. [PMID] 21371683.
2011
Genetic and epigenetic association studies suggest a role of microRNA biogenesis gene exportin-5 (XPO5) in breast tumorigenesis.
International journal of molecular epidemiology and genetics. 2(1):9-18 [PMID] 21552306.
2010
CLOCK in breast tumorigenesis: genetic, epigenetic, and transcriptional profiling analyses.
Cancer research. 70(4):1459-68 [DOI] 10.1158/0008-5472.CAN-09-3798. [PMID] 20124474.
2010
Phenotypic effects of the circadian gene Cryptochrome 2 on cancer-related pathways.
BMC cancer. 10 [DOI] 10.1186/1471-2407-10-110. [PMID] 20334671.
2010
The core circadian gene Cryptochrome 2 influences breast cancer risk, possibly by mediating hormone signaling.
Cancer prevention research (Philadelphia, Pa.). 3(4):539-48 [DOI] 10.1158/1940-6207.CAPR-09-0127. [PMID] 20233903.
2009
Cancer-related transcriptional targets of the circadian gene NPAS2 identified by genome-wide ChIP-on-chip analysis.
Cancer letters. 284(2):149-56 [DOI] 10.1016/j.canlet.2009.04.017. [PMID] 19457610.
2009
Clock-cancer connection in non-Hodgkin’s lymphoma: a genetic association study and pathway analysis of the circadian gene cryptochrome 2.
Cancer research. 69(8):3605-13 [DOI] 10.1158/0008-5472.CAN-08-4572. [PMID] 19318546.
2009
microRNA miR-196a-2 and breast cancer: a genetic and epigenetic association study and functional analysis.
Cancer research. 69(14):5970-7 [DOI] 10.1158/0008-5472.CAN-09-0236. [PMID] 19567675.
2008
Correlating observed odds ratios from lung cancer case-control studies to SNP functional scores predicted by bioinformatic tools.
Mutation research. 639(1-2):80-8 [DOI] 10.1016/j.mrfmmm.2007.11.005. [PMID] 18191955.
2008
Non-synonymous polymorphisms in the circadian gene NPAS2 and breast cancer risk.
Breast cancer research and treatment. 107(3):421-5 [PMID] 17453337.
2007
Ala394Thr polymorphism in the clock gene NPAS2: a circadian modifier for the risk of non-Hodgkin’s lymphoma.
International journal of cancer. 120(2):432-5 [PMID] 17096334.

Contact Details

Phones:
Business:
(352) 265-0916
Emails:
Addresses:
Business Mailing:
PO Box 100287
GAINESVILLE FL 32610
Business Street:
1600 SW ARCHER RD RM 6130
GAINESVILLE FL 32610